LABP Landos Biopharma

Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation Conference

Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation Conference

BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos, will present at the upcoming Raymond James Virtual Human Health Innovation Conference on Monday, June 21, 2021 at 2:00 PM EDT.

A live webcast of the presentation will be accessible through the Investors/Media section of the Company’s website at . Following the event, the webcast will be archived on the Landos website.

About Landos Biopharma

Landos Biopharma is a clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases. LANCE has discovered new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. Landos Biopharma has 17 active development programs targeting these novel pathways at the interface of immunity and metabolism. Lead asset omilancor is a novel gut-restricted small molecule drug candidate for the treatment of ulcerative colitis, Crohn’s disease and Eosinophilic Esophagitis that targets the LANCL2 pathway. NX-13 is a novel, gut-restricted small molecule drug candidate for the treatment of inflammatory bowel disease, that targets the NLRX1 pathway. Additional candidates are in development for the treatment of lupus nephritis, rheumatoid arthritis, multiple sclerosis, and diabetes. For more information, please visit .

Contacts:

Michael K. Levitan (investors)

Solebury Trout

646-378-2920

Hannah Gendel (media)

Solebury Trout

646-378-2943



EN
14/06/2021

Underlying

LABPLandos Biopharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Landos Biopharma

 PRESS RELEASE
Free
LABP Landos Biopharm...

AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfoli...

AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases - Landos’ lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC) NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with aut...

March 25, 2024 1 EN
 PRESS RELEASE
Free
LABP Landos Biopharm...

Landos Biopharma Provides Business Update and Reports Fourth Quarter a...

Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results Top-line Results from the NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into mid-2025 NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or “the Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and reported financial results for the fourth quarter...

March 21, 2024 1 EN
 PRESS RELEASE
Free
LABP Landos Biopharm...

Landos Biopharma to Present New Data on Immunometabolism at the 19th A...

Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis Organisation Six Presentations Highlight Landos’ Leadership in Targeting Immunometabolic Pathways as Novel Treatments for Autoimmune Diseases with Focus on Ulcerative Colitis NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that six abstracts were accepted for poster presentatio...

January 8, 2024 1 EN
 PRESS RELEASE
Free
LABP Landos Biopharm...

Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerati...

Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn’s and Colitis NX-13, a Novel, Oral, NLRX1 Agonist, was Observed to be Well Tolerated and Demonstrated Early Signs of Rapid Symptomatic Relief and Endoscopic Improvement in Patients with Ulcerative Colitis NEXUS Phase 2 Proof-of-Concept Study is Ongoing, with Top-Line Readout Expected in Q4 2024 NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune dis...

November 21, 2023 1 EN
 PRESS RELEASE
Free
LABP Landos Biopharm...

Landos Biopharma Provides Company Update and Reports Third Quarter 202...

Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Remains On Track with Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the quarter ended September 30, 2023. “The NX-...

November 9, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch